Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (4066)	6/7/2001 9:18:14 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 52153

Hi MZ, When I looked at both MEDX and ABGX the manufacturing ability seemed a very significant plus for MEDX. I own it. That you agree makes me think I might have gotten one right. ;-) (Have traded in and out of ABGX.) The other advantage that MEDX has is a lower cash burn rate relative to share price. That said, the valuation of the two is so difficult that I can't have any certainty that ABGX is not worth the difference. (MC, ABGX $3.8B and MEDX $2.3 B) ij